Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus

• Status: Completed
• Trial end date: 2005-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the safety and efficacy of daptomycin, an antibiotic, to standard therapy in subjects who have infective endocarditis or bacteremia due to Staphylococcus aureus (S. aureus).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cubist Pharmaceuticals LLC
• Treatments: Daptomycin

Criteria

Inclusion Criteria:

• Documented S. aureus bacteremia within 2 calendar days of the first dose of study medication

Exclusion Criteria:

• Subjects with a creatinine clearance of less than 30 ml/min

• Subjects with pneumonia

• Pregnant, nursing, or lactating

• Documented history of allergy or intolerance to penicillin or vancomycin

• Subjects with osteomyelitis